Aardvark Therapeutics, Inc. Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Tien-Li Lee
- Full Time Employees
- 40
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4370 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Feb 13, 2025
- CIK
- 0001774857
- Website
- aardvarktherapeutics.com
- Similar Companies
- Business
- Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that activate innate homeostatic pathways to suppress hunger for the treatment of metabolic diseases including Prader-Willi Syndrome (PWS) hyperphagia, obesity, and obesity-related conditions; the company offers ARD-101, an oral TAS2R bitter taste receptor agonist in Phase 3 clinical development primarily for hyperphagia in PWS via localized gut hormone release and gut-brain signaling to inhibit hunger discomfort; ARD-201, a planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor advancing into two Phase 2 trials (POWER and STRENGTH) to address GLP-1RA limitations such as weight regain post-discontinuation through weight maintenance and loss promotion; and exploratory programs like WE-868 targeting hunger-associated indications and complementary anti-appetite therapies. Founded in 2017 and headquartered in San Diego, California, Aardvark Therapeutics operates principally in the United States with a pipeline directed at endocrinology and rare genetic disorders, targeting patients with insatiable hunger in PWS and broader metabolic obesity markets. Recent developments include presentation of positive ARD-101 clinical data and ARD-201 preclinical results at ObesityWeek 2025 demonstrating metabolic benefits; reporting of third-quarter 2025 financial results with pipeline updates advancing Phase 2 trials for ARD-201; an oversubscribed $85 million Series C financing in May 2024 led by Decheng Capital to support clinical progression; a $29 million Series B funding in 2021 led by Sorrento Therapeutics; Nasdaq debut in February 2025; and inducement grants under NASDAQ rules in 2025 to bolster executive talent.
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward
FDA Halts Aardvark Therapeutics Rare Disease Study
FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates